Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Recent & Breaking News (OTCPK:SNYNF)

Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting

PR Newswire November 8, 2015

Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes

PR Newswire November 6, 2015

Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015

PR Newswire November 5, 2015

Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement

PR Newswire November 3, 2015

Sanofi Grew Sales and Business EPS in Q3 2015

PR Newswire October 29, 2015

Sanofi - Q3 2015 Results

PR Newswire October 29, 2015

Sanofi US Issues Voluntary Nationwide Recall of Auvi-Q® Due to Potential Inaccurate Dosage Delivery

PR Newswire October 28, 2015

Sanofi Pasteur and the Infectious Disease Research Institute Partner on a Global-Health, Open-Innovation, Vaccine Research & Development Center

PR Newswire October 15, 2015

Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme's Lemtrada® (alemtuzumab) in Clinical Trials

Business Wire October 8, 2015

New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis

Business Wire October 7, 2015

Genzyme Introduces "vs.MS," a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed Care

Business Wire October 5, 2015

Sanofi Announces Launch of Authorized Generic Version of Arava® (Leflunomide) Tablets

PR Newswire October 1, 2015

Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe

Business Wire October 1, 2015

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

PR Newswire September 28, 2015

More Than 50 Presentations of New Data from Genzyme's Multiple Sclerosis Franchise to be Featured at ECTRIMS

Business Wire September 23, 2015

Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015

PR Newswire September 1, 2015

Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes

PR Newswire August 31, 2015

Relypsa Enters Two-Year Detailing Agreement With Sanofi in the United States

GlobeNewswire August 10, 2015

Sanofi's Insulin Toujeo® now Available for the Treatment of Adults with Diabetes in the UK

PR Newswire August 4, 2015

New Analysis Reports Lower Rates of Serious Cardio-Respiratory Events Among Study Participants Administered Higher-Dose Influenza Vaccine

PR Newswire August 3, 2015